Updates are available Correction dated 2024-05-02

Article History

Received: 17 November 2023

Accepted: 5 February 2024

First Online: 6 March 2024

Change Date: 2 May 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40122-024-00605-6

Declarations

:

: Piero Barbanti reports personal compensation for consulting, serving on a scientific advisory board, speaker panels, travel grants, research support, collaborated for clinical trials, or other activities with AbbVie, Alder, Allergan, Amgen, Angelini, Assosalute, Bayer, Biohaven, ElectroCore, Eli Lilly, Fondazione Ricerca e Salute, GSK, Lundbeck, Lusofarmaco, 1MED, MSD, New Penta, Noema Pharma, Novartis, Pfizer, Stx-Med, Teva, Visufarma, Zambon and serves as President with Italian Association of Headache Sufferers. Gianni Allais received fees and honoraria from AbbVie, Allergan, Eli Lilly, Gam Farma, Lundbeck, MSD Organon, Novartis, Pfizer, Teva. Sabina Cevoli received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan/Abvie, Angelini, Lilly, Lundbeck, Novartis, Pfizer and Teva. Simona Guerzoni received fees and honoraria from Novartis, Allergan, Teva, Eli Lilly, Pfizer, Lundbeck. Massimiliano Venieri received honoraria for speaker panels from Lusofarmaco, Angelini, Novartis, Pfizer, Biogen and Roche. Fabrizio Valeriani received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Allergan/AbbVie, Amgen, Angelini, Lilly, Lundbeck, Novartis, Pfizer and Teva.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.